KBC Group’s Meridian Bioscience Inc VIVO Stock Holding History

KBC Group’s Portfolio VIVO Stock Details VIVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-3,728	Closed	-$124K	–	1547
2022 Q4	$124K	Hold	3,728	–	–	﹤0.01%	1128
2022 Q3	$118K	Hold	3,728	–	–	﹤0.01%	1129
2022 Q2	$113K	Buy	+3,728	New	+$101K	﹤0.01%	1181
2016 Q1	–	Sell	-1,543	Closed	-$32K	–	1311
2015 Q4	$32K	Hold	1,543	–	–	﹤0.01%	1215
2015 Q3	$26K	Sell	1,543 -26	-2%	-$475	﹤0.01%	1284
2015 Q2	$29K	Hold	1,569	–	–	﹤0.01%	1348
2015 Q1	$30K	Hold	1,569	–	–	﹤0.01%	1303
2014 Q4	$26K	Buy	+1,569	New	+$26.9K	﹤0.01%	1403
2014 Q1	–	Sell	-792	Closed	-$21K	–	1356
2013 Q4	$21K	Hold	792	–	–	﹤0.01%	1290
2013 Q3	$19K	Hold	792	–	–	﹤0.01%	1228
2013 Q2	$17K	Buy	+792	New	+$17.1K	﹤0.01%	1216

Other funds holding VIVO

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

KBC Group's VIVO Position: Q1 2023 in Review

KBC Group sold out of Meridian Bioscience Inc (VIVO) in Q1 2023, closing a stake of 3,728 shares — an estimated $124K sold.

KBC Group first reported a position in VIVO in Q2 2013 and held it in 11 quarters. The position peaked at $124K in Q4 2022. 2 funds tracked by Wall St. Rank hold VIVO as of Q1 2023.

KBC Group reported no remaining Meridian Bioscience Inc position as of Q1 2023 after selling out during the quarter.
KBC Group sold 3,728 Meridian Bioscience Inc shares in Q1 2023, an estimated $124K.
KBC Group first reported a position in Meridian Bioscience Inc in Q2 2013 and held it in 11 quarters.
KBC Group's Meridian Bioscience Inc position peaked at $124K in Q4 2022.
2 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2023.

Based on KBC Group's 13F filing for Q1 2023, filed 4 May 2023.